why choose us

First received: April 18, 2023

Clinical Trial: Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK

Study Status: Completed

Recruit Status: RECRUITING

Condition: Myoclonus Epilepsies, Progressive

Study Type: INTERVENTIONAL


Official Title: A Randomized, Double-blind, Placebo-controlled, Crossover Study of the Effects of Single Doses of AUT00201 in Patients With Myoclonus Epilepsy and Ataxia Due to Potassium (K+) Channel Mutation (MEAK)

Brief Summary: A randomized, double-blind, placebo-controlled, crossover study to assess the safety, tolerability, and pharmacokinetics of single doses of AUT00201 at 100 mg or matching placebo in patients with myoclonus epilepsy and ataxia due to potassium channel mutation (MEAK).

Read more